Showing results (721-730 of 3,867) with videos related to

Sort By:
Pageof 387
Alzheimer'S Research & Therapy|February 12, 2022
Intracranial internal carotid artery calcification is not predictive of future cognitive declineFarzaneh Rahmani, Marina Nguyen, Charles D Chen, et al.
Plos One|April 29, 2011
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosisRebecca Craig-Schapiro, Max Kuhn, Chengjie Xiong, et al.
Radiation Oncology (London, England)|January 10, 2015
Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patientsVivek Verma, Jingxia Liu, Laura Eschen, et al.
MDM Policy & Practice|August 15, 2017
Show Me My Health Plans: Using a Decision Aid to Improve Decisions in the Federal Health Insurance MarketplaceMary C Politi, Marie D Kuzemchak, Jingxia Liu, et al.
Journal of Surgical Oncology|July 25, 2019
Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG)Roheena Z Panni, Alexandra G Lopez-Aguiar, Jingxia Liu, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 18, 2019
Composite Length of Stay, An Outcome Measure of Postoperative and Readmission Length of Stays in PancreatoduodenectomyGregory A Williams, Jingxia Liu, William C Chapman, et al.
Journal of Gastrointestinal Oncology|March 17, 2020
Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinomaPatrick Grierson, Andrea Teague, Rama Suresh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 31, 2016
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell TransplantIbraheem H Motabi, Armin Ghobadi, Jingxia Liu, et al.
Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2024
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell LymphomasNicole Foley, Peter A Riedell, Nancy L Bartlett, et al.
Pageof 387